When Diana Hill went looking for significant new commercial opportunities in New Zealand's meat industry, she decided she'd better get down and dirty, so she spent a month in a meat processing plant asking where the hell the next billion dollar business was. [ + ]

Ruth Beran discovers how one of Australia's great bioentrepreneurs has moved from inspiring shareholders to inspiring a nation. [ + ]

Australian Biotechnology News journalist Ruth Beran asked Axon Instruments founder Alan Finkel if he had any advice for Australian companies with an eye on the world stage. Here is his reply. [ + ]

A young American genetist is embarking on a project which could solve many of the mysteries of human history, and give each of us a chance to find out about our our oldest ancestors. [ + ]

High throughput screening of drugs of abuse is performed at St Olav Hospital by LC/MS. Typically done by immunoassay, this overview describes the procedures for using this highly selective and quantitative LC/MS methodology

This study describes an experimental set-up that allows filter tips to be tested for their separation performance in relation to aerosols

In 2000, a research team led by University of Queensland molecular geneticist Prof Robert Birch first inserted a gene from the plant-dwelling bacterium Pantoea dispersa into sugarcane cells, aiming to create plants that would synthesise isomaltulose, instead of sucrose. [ + ]

Queensland researchers are developing GM cultivars of three tropical crops - pineapple, papaw and banana, to solve disease and quality problems. [ + ]

Sugar CRC CEO Dr Peter Twine sees the industry - with a little help from its friends in the research community - leading Australia into what he calls the 'carbohydrate economy'. [ + ]

The old joke about Queensland being a decade plus one hour behind the southern states during daylight saving is fast fading from the repertoire of state-vs-state humour. [ + ]

Brian McNamee has been at the helm of Australia's oldest - and now biggest - life-sciences company, CSL, for 15 years. He guided the company through its public listing in 1994 and has overseen its growth to a market capitalisation of $6.8 billion. He spoke with Melissa Trudinger about CSL's research and development programs, and his vision for the company's future. [ + ]

The prospect of therapies based on human stem cells holds great promise for revolutionising the practice of medicine, says Silviu Itescu. [ + ]

The pressure of healthcare costs in the future will bring better health outcomes, predict Kieran Schneemann and Brendan Shaw. [ + ]

The human embryonic stem (ES) cell field is one of the most exciting and complex opportunities of today's biomedical industry, write Peter Mountford and Kenzo Nakajima. [ + ]

Selected ion flow tube mass spectrometry (SIFT-MS) instruments represent the latest generation in the evolutionary path of analytical instruments. SIFT-MS is complementing existing GC-based analytical services as well as opening up entirely new services